ReviewRheumatology (Oxford, England)2018
What is new in pain modification in osteoarthritis?
Review in Rheumatology (Oxford, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis.Medicina (Kaunas, Lithuania) · 2021Trial
- A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip.Osteoarthritis and cartilage open · 2024Article
- Research Trends and Foci in Osteoarthritis Pain from 2012 to 2022: Bibliometric and Visualization Study.Journal of pain research · 2023Article
- A case report of cryoablation for chronic shoulder pain due to osteoarthritis.Interventional pain medicine · 2022Article
- Interleukin-6 signaling mediates cartilage degradation and pain in posttraumatic osteoarthritis in a sex-specific manner.Science signaling · 2022Article
- Review
- Genetic pain loss disorders.Nature reviews. Disease primers · 2022Review
- [Pain reduction through physical medicine : Update on the evidence].Zeitschrift fur Rheumatologie · 2022Review
- Associations between joint pathologies and central sensitization in persons with hand osteoarthritis: results from the Nor-Hand study.Rheumatology (Oxford, England) · 2022Article
- Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials.Therapeutic advances in musculoskeletal disease · 2022Article
- New developments in osteoarthritis pharmacological therapies.Rheumatology (Oxford, England) · 2021Review
- A harm reduction model to assess the impact of new treatments for pain over standard of care among patients with osteoarthritis.Journal of managed care & specialty pharmacy · 2021Article
- An up to date on clinical prospects and management of osteoarthritis.Annals of medicine and surgery (2012) · 2021Review
- [Pain therapy using anti-nerve growth factor antibodies? : Pain research in a dilemma].Schmerz (Berlin, Germany) · 2021Article
- Prospects for Therapies in Osteoarthritis.Calcified tissue international · 2021Review
- The burden of hip and knee osteoarthritis in Finnish occupational healthcare.BMC musculoskeletal disorders · 2021Article
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.International journal of molecular sciences · 2021Review
- Local Administration of Low-Dose Nerve Growth Factor Antibody Reduced Pain in a Rat Osteoarthritis Model.International journal of molecular sciences · 2021Article
- New Trends in Pharmacological Treatments for Osteoarthritis.Frontiers in pharmacology · 2021Review
- Mesenchymal stem cells in osteoarthritis therapy: a review.American journal of translational research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
There is a big need for the development of novel therapies for the safe management of chronic pain associated with OA. Here we reviewed PubMed (2015 onward) and ClinicalTrials.gov for ongoing and recently completed trials where pain in OA is the primary outcome measure. Three broad categories were identified: biological therapies, small molecules and cryoneurolysis. The most promising new strategy is blockade of nerve growth factor with antibodies. Two anti-nerve growth factor antibodies, tanuzemab and fasinumab, are in active development after the 2010 hold on trials was lifted in 2015. In addition, several active clinical trials are testing distinct mechanism-based interventions, including cytokine inhibition, selective μ, δ or κ opioid receptor agonists, zoledronate and intra-articular capsaicin. In addition to pharmacological approaches, cryoneurolytic strategies that directly target peripheral nerves may play a role in OA pain management, but efficacy profiles and long-term effects of such treatments need more study. Clearly, the therapeutic landscape for OA pain is rapidly expanding. Since symptomatic OA is a heterogeneous disease, the challenge will be to identify patients that will benefit the most from specific approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.